North Texas Infectious Diseases Consultants

North Texas Infectious Diseases Consultants is the leading Infectious Disease medical group in Dallas. Our physicians specialize in all Infectious Diseases

[North Texas Infectious Diseases Consultants @NTIDC]

Top 10 HIV Clinical Developments of 2023. #HIV Read more at https://t.co/KfPTW9qIDN

[North Texas Infectious Diseases Consultants @NTIDC]

Demystifying mRNA Medicine: Setting the Record Straight. https://t.co/TDZEf3Yv7P

[North Texas Infectious Diseases Consultants @NTIDC]

Super-contagious new omicron subvariant will spark another wave, experts say.
https://t.co/HNylAAHVyf

[North Texas Infectious Diseases Consultants @NTIDC]

A prescription for prolonged sitting: A five-minute stroll every half hour.
https://t.co/LbG9l6e9kr

[North Texas Infectious Diseases Consultants @NTIDC]

New HIV infection rates are falling, and treatments are improving. But do we have the political will to end HIV/AIDS?
Dallas Voice talked with Bryan King of North Texas Infectious Disease Consultants.
Read more at https://t.co/00XPf0bSxt

[North Texas Infectious Diseases Consultants @NTIDC]

TMA Puts Physicians' Wellness First With New Program.
https://t.co/2cgfwN7UHb

[North Texas Infectious Diseases Consultants @NTIDC]

Dallas County Sheriff's Office investigating possible case of monkeypox from person in custody.
https://t.co/kWVwLSgAcQ

[North Texas Infectious Diseases Consultants @NTIDC]

The Research Department at North Texas ID Consultants is proud to be listed in the New England Journal of Medicine as collaborators with this new, and exciting long acting antiretrovirals for the treatment of HIV. https://t.co/tYzNRpEF4r

[North Texas Infectious Diseases Consultants @NTIDC]

Is the COVID-19 Vaccine Safe? #covid19 #vaccinesafe Read more at https://t.co/ya4KNhiz8x

[North Texas Infectious Diseases Consultants @NTIDC]

Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant. #covid19 #omicronvariant Read more at https://t.co/43evLPwmfN

[North Texas Infectious Diseases Consultants @NTIDC]

Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals. Read more at https://t.co/33L9iDyLeL

[North Texas Infectious Diseases Consultants @NTIDC]

New phase 3 analyses show that a single dose of REGEN-COV® (Casirivimab and Imdevimab) provides long-term protection against COVID-19. Read more at https://t.co/8kCVNU9YtE

[North Texas Infectious Diseases Consultants @NTIDC]

Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. Read more at https://t.co/KK4HcZdQA9

[North Texas Infectious Diseases Consultants @NTIDC]

Pfizer plans to submit data on a 4th Covid shot to FDA. Read more at https://t.co/pe2xRZYrhf

[North Texas Infectious Diseases Consultants @NTIDC]

Omicron BA.2 sub-variant now nearly a quarter of new COVID cases in U.S., CDC estimates. #covid Read more at https://t.co/Fgn0QG0GwA

[North Texas Infectious Diseases Consultants @NTIDC]

UT Southwestern confirmed two cases of BA.2 in North Texas Thursday, a new mutation of the omicron variant of the coronavirus.
https://t.co/eqTwqyVz0u

[North Texas Infectious Diseases Consultants @NTIDC]

Here’s what to know about BA.2, a little-understood sub-type of omicron.
https://t.co/aCH4sIH79H

[North Texas Infectious Diseases Consultants @NTIDC]

Coronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant.
https://t.co/aJJCvEqrsY

[North Texas Infectious Diseases Consultants @NTIDC]

Pfizer and BioNTech launch clinical trial of Covid vaccine targeting omicron. North Texas ID consultants are participating in both booster trials.
https://t.co/izJxNuntAQ

[CDC @CDCgov]

New @CDCMMWR found when #Omicron first began circulating, adults who got a #COVID19 booster dose had 5x the protection against infection compared w/ adults who were not vaccinated. All eligible people should stay up to date w/ COVID-19 vaccination. More: https://t.co/kDgAdWsPpx.